Cite
HARVARD Citation
Dreyling, M. et al. (n.d.). Long‐term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2‐year follow‐up of the CHRONOS‐1 study. American journal of hematology. 95 (4), pp. 362-371. [Online].